[1]刘向阳,曹宏伟,王 莉,等.非诺贝特联合非布司他治疗高尿酸血症合并高脂血症有效性及安全性评价*[J].陕西医学杂志,2020,49(9):1149-1152.[doi:DOI:10.3969/j.issn.1000-7377.2020.09.024]
　LIU Xiangyang,CAO Hongwei,WANG Li,et al.Evaluation of the efficacy and safety of fenofibrate combined with febuxostat in treatment of hyperuricemia with hyperlipidemia[J].,2020,49(9):1149-1152.[doi:DOI:10.3969/j.issn.1000-7377.2020.09.024]
点击复制

非诺贝特联合非布司他治疗高尿酸血症合并高脂血症有效性及安全性评价*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年9期
页码:
1149-1152
栏目:
药物与临床
出版日期:
2020-09-01

文章信息/Info

Title:
Evaluation of the efficacy and safety of fenofibrate combined with febuxostat in treatment of hyperuricemia with hyperlipidemia
作者:
刘向阳; 曹宏伟; 王 莉; 赖敬波; 姬秋和; 李晓苗△
空军军医大学西京医院内分泌代谢科(西安 710032)
Author(s):
LIU Xiangyang; CAO Hongwei; WANG Li; et al.
Department of Endocrinology,Xijing Hospital,Air Force Medical University(Xi'an 710032)
关键词:
非诺贝特;  联合;  非布司他;  治疗;  高尿酸血症;  高脂血症
Keywords:
Fenofibrate;  Combination;  Febuxostat;  Therapy;  Hyperuricemia;  Hyperlipidemia
分类号:
R589.7
DOI:
DOI:10.3969/j.issn.1000-7377.2020.09.024
文献标志码:
A
摘要:
目的:观察非布司他治疗效果不佳的高尿酸血症(HUA)合并高脂血症患者加用非诺贝特治疗的有效性和安全性。方法:80例HUA患者作为研究对象,随机分为治疗组(40例)和对照组(40例)。对照组单用非布司他治疗,治疗组在非布司他的基础上加用非诺贝特治疗,两组同时进行健康教育和生活方式指导。分别于基线和治疗12周后超声检查肝脏,测量体质量、收缩压(SBP),测定血尿酸(SUA)、甘油三酯(TG)、空腹血糖(FPG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、总胆固醇(TC)、肝肾功能和血常规,并在两组间进行比较。结果:治疗12周后,两组患者体质量、SUA和TG水平均较治疗前显著降低,差异均有统计学意义(P<0.05)。治疗组SUA、TG均显著低于对照组,差异均有统计学意义(P<0.05)。治疗组在体质量、SBP、TC、HDL-C、LDL-C等方面的变化明显优于对照组(P<0.05)。治疗组SUA低于420 μmol/L的患者比例为100%,其中92.3%的患者低于360 μmol/L; 脂肪肝好转率:轻度23%,中度11%,重度8%。对照组70%的患者SUA低于420 μmol/L,27.5%的患者低于360 μmol/L; 脂肪肝好转率:轻度15%,中度7.5%,重度2%。两组尿酸达标率、脂肪肝好转率比较,差异均有统计学意义(P<0.05)。结论:对于单用非布司他治疗效果不佳的HUA合并高脂血症患者,加用非诺贝特在降低血脂的基础上能够有效降低SUA,改善脂肪肝,且不增加不良反应。
Abstract:
Objective:To observe the efficacy and safety of fenofibrate in patients with hyperuricemia(HUA)combined with hyperlipidemia inadequately controlled by febuxostat.Methods:80 patients with HUA were randomly divided into treatment group(40 cases)and control group(40 cases).The control group was treated with febuxostat alone.The treatment group was treated with fenofibrate on the basis of febuxostat.The two groups were given health education and lifestyle guidance at the same time.At baseline and 12 weeks after treatment,the liver of all the patients were examined by ultrasonography,and the body weight,systolic blood pressure(SBP),serum uric acid(SUA),triglyceride(TG),fasting plasma glucose(FPG),blood lipids(TG,TC,HDL-C,LDL-C),liver and kidney function,and blood routine were measured.The results were compared between the two groups.Results:After 12 weeks of treatment,the body weight,SUA and TG levels of the two groups were significantly lower than those before treatment,and the differences were statistically significant(P<0.05); the SUA and TG in the treatment group were significantly lower than those in the control group,and the differences were statistically significant(P<0.05); the changes in body weight,SBP,TC,HDL-C and LDL-C in the treatment group were significantly better than those in the control group(P<0.05).The percentage of patients with SUA below 420 μmol/L in the treatment group was 100%,of which 92.3% were below 360 μmol/L; the improvement rate of fatty liver:mild 23%,moderate 11%,severe 8%.The SUA of 70% of patients in the control group was lower than 420 μmol/L,and 27.5% of patients were lower than 360 μmol/L; the improvement rate of fatty liver:mild 15%,moderate 7.5%,and severe 2%.The differencesbetween the two groups were statistically significant(P<0.05).Conclusion:For patients with HUA and hyperlipidemia who have poor treatment with febuxostat alone,the addition of fenofibrate can effectively reduce SUA,improve fatty liver,without increasing adverse reactions.

参考文献/References:

[1] 吕雪霞,胡吉东.高尿酸血症患病率调查及临床影响分析[J].临床检验杂志:电子版, 2020, 9(1):34-35.
[2] 凡利敏,周春美,黄 薇,等.健康体检人群血清尿酸水平及高尿酸血症的分布特点分析[J].标记免疫分析与临床,2020,27(2):252-256.
[3] Robinson PC,Dalbeth N.Febuxostat for the treatment of hyperuricaemia in gout[J].Expert Opinion on Pharmacotherapy,2018,19(11):1289-1299.
[4] 陈 亮,张 凤.桂枝芍药知母汤联合非布司他治疗痛风临床研究[J].陕西中医,2018,39(4):488-490.
[5] 邵思思,黄蔚霞,项协隆,等.丹参注射液联合非布司他治疗慢性尿酸性肾病的疗效及安全性研究[J].中华全科医学,2018,16(11):1843-1846.
[6] 吕 赛,周玉杰,刘 巍.高尿酸血症、代谢综合征与冠心病的研究进展[J].心肺血管病杂志,2018,37(1):76-78.
[7] Pascart T,Lioté F.Gout:state of the art after a decade of developments[J].Rheumatology(Oxford),2019,58(1):27-44.
[8] Feher MD,Hepburn AL,Hogarth MB,et al.Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout[J].Rheumatology(Oxford,England),2003,42(2):321-325.
[9] 宋春利.非诺贝特对脂肪肝合并痛风患者血甘油三酯和尿酸水平的影响[J].陕西医学杂志,2011,40(10):1423-1424.
[10] 吕 颖,程曼丽,赵 朝,等.长期小剂量阿托伐他汀联合非诺贝特对脂代谢异常高危人群血脂的影响[J].陕西医学杂志,2011,40(2):207-209.
[11] 中华医学会内分泌学分会.高尿酸血症和痛风治疗的中国专家共识[J].中华内分泌代谢杂志,2013,29(11):913-920.
[12] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)[J].中华健康管理学杂志,2017,11(1):7-28.
[13] Kawamura Y,Nakaoka H,Nakayama A,et al.Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout[J].Annals of the Rheumatic Diseases,2019,78(10):1430-1437.
[14] Weisman A,Tomlinson GA,Lipscombe LL,et al.Association between allopurinol and cardiovascular outcomes and all-cause mortality in diabetes:a retrospective,population-based cohort study[J].Diabetes,Obesity & Metabolism,2019,21(6):1322-1329.
[15] 梅丽萍,孙星达,李 彬.高尿酸血症与非酒精性脂肪性肝病的相关性研究进展[J].中国慢性病预防与控制,2018,26(8):620-623.
[16] 郭凯锋,陈海冰.高尿酸血症、痛风与非酒精性脂肪肝的相关性研究进展[J].中华糖尿病杂志,2015,7(9):581-584.
[17] 周 薇,单年春,谭 英,等.医务工作者高脂血症与高尿酸血症关系的纵向研究[J].中华健康管理学杂志,2018,12(3):252-258.
[18] 程亚明,王 骥.马鞍山中青年体检人群中高尿酸血症与糖尿病检出率及二者相关性分析[J].解放军预防医学杂志,2019,37(11):165-166.
[19] Xu CF,Yu CH,Xu L,et al.Hypouricemic therapy:a novel potential therapeutic option for nonalcoholic fatty liver disease[J].Hepatology,2010,52(5):1865-1866.
[20] 辛 雷,梁菁菁,高 颖,等.降尿酸治疗对肾脏保护作用的研究进展[J].中国全科医学,2019,22(17):2025-2029.
[21] Xu S,Liu X,Jie M.A phase 3,multicenter,randomized,allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia[J].International Journal of Rheumatic Diseases,2015,18(6):669-678.
[22] 张静雯,汪 宁,邱红霞,等.非布司他治疗早期糖尿病肾病合并高尿酸血症疗效及对患者肾功能影响研究[J].陕西医学杂志,2020,49(2):209-211,230.
[23] 韩亭亭,李阳雪,郑 爽,等.非诺贝特改善脂蛋白脂酶基因杂合敲除小鼠胰岛素抵抗及其机制研究[J].中华内分泌代谢杂志,2018,34(10):867-871.
[24] Zheng S,Ren X,Han T,et al.Fenofibrate attenuates fatty acid-induced islet β-cell dysfunction and apoptosis via inhibiting the NF-κB/MIF dependent inflammatory pathway[J].Metabolism,2017,77:23-38.
[25] Waldman B,Ansquer JC,Sullivan DR,et al.Effect of fenofibrate on uric acid and gout in type 2 diabetes:a post-hoc analysis of the randomised,controlled FIELD study [J].Lancet,Diabetes & Endocrinolog,2018,6(4):310-318.
[26] Jatuworapruk K,Grainger R,Dalbeth N,et al.Development of a prediction model for inpatient gout flares in people with comorbid gout [J].Ann Rheum Dis,2020,79(3):418-423.
[27] 中华医学会内分泌学分会.中国高尿酸血症与痛风诊疗指南(2019)[J],中华内分泌代谢杂志,2020,36(1):1-12.
[28] Qaseem A,McLean RM,Starkey M,et al.Diagnosis of acute gout:a clinical practice guideline from the american college of physicians[J].Annals of Internal Medicine,2017,166(1):52-57.
[29] 刘向阳,高 彬,黄新喜,等.参加药物临床试验对糖尿病患者治疗效果及认知行为的影响[J].解放军预防医学杂志,2016,34(5):697-699.

备注/Memo

备注/Memo:
*国家自然科学基金资助面上项目(81573746)
更新日期/Last Update: 2020-09-02